Eli Lilly (LLY)
(Delayed Data from NYSE)
$818.93 USD
-10.81 (-1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$818.93 USD
-10.81 (-1.30%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Top Ranked Growth Stocks to Buy for May 4th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, May 4th:
United Therapeutics (UTHR) Q1 Earnings Rise, Sales Drop Q/Q
by Zacks Equity Research
United Therapeutics' (UTHR) earnings per share rise in the first quarter. Sales drop sequentially due to unfavorable timing of distributor orders. Shares sink almost 7%.
Top Ranked Growth Stocks to Buy for May 2nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, May 2nd:
Top Ranked Growth Stocks to Buy for April 30th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 30th:
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
by Zacks Equity Research
The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.
Lilly (LLY) Tops on Q1 Earnings, Raises '18 View, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats estimates for both earnings and sales in Q1 and raises guidance for 2018. Shares rise in pre-market trading.
Eli Lilly (LLY) Tops Q1 Earnings & Sales, Ups 2018 View
by Kinjel Shah
Eli Lilly (LLY) beat estimates for both earnings and sales in Q1 and raised the guidance for 2018. Shares declined in pre-market trading.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN
by Zacks Equity Research
Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.
Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lilly's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Top Ranked Growth Stocks to Buy for April 20th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 20th:
Amgen's Aimovig Reduces Episodic Migraine in 30% Patients
by Zacks Equity Research
Amgen (AMGN) releases full data from the phase IIIb trial, evaluating the efficacy and safety of Aimovig on patients suffering episodic migraine with multiple treatment failures.
5 Drug Stocks Poised to Surpass on Earnings This Quarter
by Zacks Equity Research
The outlook for the upcoming first-quarter results looks bright.
Merck's Keytruda Betters Survival in Lung Cancer Combo Study
by Zacks Equity Research
Merck (MRK) releases complete data from a phase III study showing Keytruda in combination with Lilly's Alimta and platinum chemotherapy reducing death risk by half compared with only chemotherapy.
Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
by Zacks Equity Research
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
Merck's Keytruda Reduces Death Risk in Melanoma Patients
by Zacks Equity Research
Merck's (MRK) Keytruda significantly prolongs RFS and reduces the risk of disease recurrence or death by 43% versus placebo in a phase III study in high-risk stage III melanoma patients.
AbbVie's RA Candidate Meets Primary Endpoints in Phase III
by Zacks Equity Research
AbbVie's (ABBV) rheumatoid arthritis candidate, upadacitinib, meets both primary and secondary endpoints in the fourth phase III SELECT study for the given indication.
vTv Therapeutics Crashes on Alzheimer's Drug Study Failure
by Zacks Equity Research
vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.
Merck's Keytruda Offers Survival Benefit in Lung Cancer Study
by Zacks Equity Research
Merck's (MRK) phase III study showed that Keytruda monotherapy led to significantly improved overall survival (OS) as a first-line therapy in certain lung cancer patients.
Novartis and Other Drug Stocks With FDA Catalysts in April
by Kinjel Shah
With just a quarter gone by this year, the FDA has already granted approval to six new treatments.
Top Ranked Growth Stocks to Buy for April 10th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, April 10th:
Lilly's Cyramza Shows Survival Benefit in Liver Cancer Study
by Zacks Equity Research
A late-stage study evaluating Eli Lilly's (LLY) Cyramza for the second-line treatment of liver cancer patients shows that such patients derived a survival benefit with Cyramza after first-line treatment with Nexavar.
FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
by Zacks Equity Research
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy
by Zacks Equity Research
Bristol-Myers' (BMY) filing for Opdivo in combination with Yervoy gains acceptance from the FDA for treating metastatic colorectal cancer. A response is expected in July, 2018.